New Real-World study tests toripalimab combo for aggressive lung cancer

NCT ID NCT07308379

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 1,200 people with extensive-stage small cell lung cancer who are starting treatment with toripalimab plus chemotherapy. Researchers will track how long patients live without their cancer progressing and overall survival, using real-world data from medical records. The goal is to see how well this combination works outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (a PD-1 inhibitor) combined with chemotherapy
What this could lead to: If successful, this could confirm that toripalimab plus chemo helps people with extensive-stage small cell lung cancer live longer without their cancer getting worse.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. The drug may not work for everyone and can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, EXTENSIVE STAGE TORIPALIMAB

More trials for these conditions

Other studies related to the condition(s) this trial covers.